Physician Assistant Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tracee Blackburn

Dermatology Chicago, IL Physician Assistant

NPI 1396776498 CMS profile 431431

1460 North Halsted Street, Suite 505, Chicago, IL 60642

Open in the dashboard

General payments

$179,590

710 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tracee Blackburn of Chicago, IL is reported in the CMS Open Payments database as having received $179,590 across 710 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $49,600 230
2024 General $58,054 223
2023 General $39,846 135
2022 General $25,390 55
2021 General $6,683 66
2019 General $16 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tracee Blackburn
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Tracee Blackburn were reported at $49,600. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Tracee Blackburn Dermatology median Middle half National median
2019 $16 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $6,683 $377 $108–$1,108 $132
2022 $25,390 $514 $143–$1,391 $149
2023 $39,846 $607 $159–$1,674 $160
2024 $58,054 $751 $204–$1,903 $164
2025 $49,600 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $92,810 238 payments
  2. Arcutis Biotherapeutics, Inc. $23,465 65 payments
  3. Sun Pharmaceutical Industries Inc. $23,027 65 payments
  4. Genzyme Corporation $11,288 25 payments
  5. Regeneron Healthcare Solutions, Inc. $8,131 34 payments
  6. Incyte Corporation $7,278 19 payments
  7. Janssen Biotech, Inc. $2,281 42 payments
  8. AbbVie, Inc. $2,127 63 payments
  9. Pfizer Inc. $1,605 30 payments
  10. LEO Pharma Inc. $1,517 14 payments
  11. Other $6,060 115 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $76,301 84 payments
  2. Consulting Fee $59,453 53 payments
  3. Travel and Lodging $23,012 83 payments
  4. Food and Beverage $14,855 477 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $5,343 2 payments
  6. Education $626 11 payments
Products named General payments · program years 2019–2025
  1. OLUMIANT $36,544 62 payments
  2. EBGLYSS $25,291 62 payments
  3. Zoryve $23,427 64 payments
  4. ILUMYA $21,807 55 payments
  5. DUPIXENT $10,268 23 payments
  6. OPZELURA $4,826 15 payments
  7. TALTZ $3,078 45 payments
  8. TREMFYA $2,381 41 payments
  9. VTAMA $1,516 12 payments
  10. LITFULO $1,438 22 payments
  11. Other $7,443 227 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Dermatology: 534

Drug cost

$75,601

Median for Dermatology: $67,151

Branded share of claims

100%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 11 $75,601

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ILUMYA
$13,184 — —
DUPIXENT
$9,451 — —
OLUMIANT
$6,767 — —
Zoryve
$6,337 — —
TALTZ
$2,464 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

710 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record